Published in Lancet on February 28, 1980
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
Anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry (1980) 1.20
Inhibitory effect of alpha-fetoprotein on the binding of myasthenia gravis antibody to acetylcholine receptor. Proc Natl Acad Sci U S A (1980) 0.79
Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture. Nature (1978) 3.29
Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med (1991) 2.05
Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. Ann Neurol (1977) 1.84
Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 1.66
Adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary. Gynecol Oncol (1998) 1.65
Muscular dystrophy in young girls. Neurology (1970) 1.60
Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol (1975) 1.59
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
Ovum capture and fertility following microsurgical fimbriectomy in the rabbit. Fertil Steril (1981) 1.53
Clinical significance of endometrial fluid collections in asymptomatic postmenopausal women. J Ultrasound Med (1996) 1.53
Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol (1997) 1.51
The thymus in myasthenia gravis. Evidence for altered cell populations. N Engl J Med (1974) 1.50
Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology (1998) 1.50
Ovarian cyst formation in two pre-menopausal patients treated with tamoxifen for breast cancer. Hum Reprod (1994) 1.49
Cell type-specific markers for human glial and neuronal cells in culture. Lab Invest (1980) 1.49
Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol (1996) 1.48
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol (1994) 1.48
Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol (1998) 1.46
Hydrosalpinx with adnexal torsion in an adolescent virgin patient--A diagnostic dilemma: case report and review of the literature. J Pediatr Adolesc Gynecol (2006) 1.45
High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology (1992) 1.43
Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature (1975) 1.43
An association between multiple sclerosis and type I diabetes mellitus. J Neurol (1992) 1.42
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol (2001) 1.41
Lack of hemispheric localizing value of the palmomental reflex. Neurology (2005) 1.40
Long-term transvaginal ultrasonographic endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment. Gynecol Oncol (1999) 1.40
Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. Br J Obstet Gynaecol (1992) 1.39
Serum Cu/Zn superoxide dismutase activity is reduced in sporadic amyotrophic lateral sclerosis patients. J Neurol Sci (1996) 1.38
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A (1994) 1.37
Cell-mediated immunity to myelin basic protein in acute disseminated encephalomyelitis. Neurology (1974) 1.35
Experimental allergic neuritis induced by sensitization with galactocerebroside. Science (1979) 1.26
Multiple sclerosis and Sjögren's syndrome: a problem in diagnosis or in definition of two disorders of unknown etiology? Ann Neurol (1990) 1.26
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (2000) 1.23
Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol (1983) 1.23
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22
Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol (1986) 1.20
Limiting dilution analysis of the frequency of antigen-reactive lymphocytes isolated from the central nervous system of Lewis rats with experimental allergic encephalomyelitis. Cell Immunol (1987) 1.20
Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med (1977) 1.20
Dissociation of antibody production from disease suppression in the inhibition of allergic encephalomyelitis by myelin basic protein. J Immunol (1970) 1.19
Delayed hypersensitivity to encephalitogenic protein in disseminated encephalomyelitis. Lancet (1968) 1.17
Inosiplex in the treatment of subacute sclerosing panencephalitis. Arch Neurol (1979) 1.16
Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol (1984) 1.16
Role of ryanodine receptor channels in Ca2+ oscillations of porcine tracheal smooth muscle. Am J Physiol (1997) 1.16
Guillain-Barré syndrome after epidural anesthesia: direct nerve root damage may trigger disease. Neurology (1985) 1.16
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (2006) 1.15
Circulating immune complexes in multiple sclerosis and other neurological diseases. Lancet (1976) 1.14
Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol (2001) 1.13
Hyperkalemic periodic paralysis and cardiac arrhythmia. Neurology (1972) 1.13
Relationship between embryo morphology and implantation rate after in vitro fertilization treatment in conception cycles. Fertil Steril (1993) 1.12
Multifocal motor nerve conduction abnormalities in amyotrophic lateral sclerosis. J Neurol Sci (1992) 1.12
Hydrometrocolpos--diagnostic and therapeutic dilemmas. J Pediatr Adolesc Gynecol (2008) 1.10
Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest (1991) 1.10
Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs. J Exp Med (1975) 1.10
In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases. N Engl J Med (1977) 1.09
T and B lymphocytes in multiple sclerosis. Clin Exp Immunol (1975) 1.09
Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis. J Immunol (1981) 1.09
Fully integrated whole blood testing by real-time absorption measurement on a centrifugal platform. Lab Chip (2006) 1.09
Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients. Isr J Med Sci (1978) 1.09
Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. Eur J Immunol (1994) 1.08
Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol (1980) 1.07
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler (2010) 1.07
Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol (1999) 1.06
Immune responses to myelin basic protein in mycobacterial-induced suppression of experimental allergic encephalomyelitis. Cell Immunol (1974) 1.06
Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol Oncol (1991) 1.05
Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci U S A (1975) 1.03
Transient global amnesia due to a dominant hemisphere tumor. Arch Neurol (1977) 1.03
HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol (1999) 1.02
VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology (2011) 1.02
In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann Neurol (1982) 1.02
Mitogens for glial cells: a comparison of the response of cultured astrocytes, oligodendrocytes and Schwann cells. Brain Res (1981) 1.02
Integrated siphon-based metering and sedimentation of whole blood on a hydrophilic lab-on-a-disk. Biomed Microdevices (2007) 1.02
Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol (1975) 1.01
Association of MS with thyroid disorders. Neurology (1999) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Immunologic mechanisms in experimental encephalomyelitis in nonhuman primates. Arch Neurol (1973) 1.00
Regulated expression of proenkephalin A in normal lymphocytes. J Immunol (1989) 0.99
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol (2001) 0.99
The impact of different types of anesthesia on in vitro fertilization-embryo transfer treatment outcome. J Assist Reprod Genet (1995) 0.99
Complete unilateral ophthalmoplegia as the presenting manifestation of Waldenström's macroglobulinemia. Neurology (1990) 0.99
Azathioprine in the treatment of myasthenia gravis. Ann Neurol (1984) 0.99
Guillain-Barré syndrome (GBS) with bilateral optic neuritis and central white matter disease. Neurology (1993) 0.99
Ictal hemiparesis. Eur Neurol (1982) 0.98
Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease? J Neurol (1988) 0.98
Neurologic manifestations of progressive systemic sclerosis. Arch Neurol (1992) 0.98
Antimyelin antibodies in neurologic diseases. Immunofluorescent demonstration. Arch Neurol (1975) 0.98
Multiple sclerosis: evidence for immunopathogenesis. Neurology (1980) 0.98
Search for anti-encephalitogen antibody in human demyelinative diseases. Neurology (1968) 0.98
Pregnancy outcome after laparoscopy or laparotomy in pregnancy. J Am Assoc Gynecol Laparosc (2003) 0.97
Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1995) 0.97
Long term culture of bovine oligodendroglia isolated with a Percoll gradient. Brain Res (1981) 0.97
Adenomatous polyposis coli I1307K mutation in Jewish patients with different ethnicity: prevalence and phenotype. Cancer (2000) 0.96
Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. Ann Neurol (1991) 0.96